VAERS reports by lot

GSK DTaP/Tdap lot DR2GR: VAERS reports

24 VAERS reports list lot DR2GR as a GSK DTaP/Tdap vaccine, received between 2022-10-24 and 2023-10-30. Data: VAERS public files through 31 December 2024 (site extract 2026-07-04).

Read this first. VAERS accepts reports from anyone, and a report does not establish that the vaccine caused the event. A lot's report count mostly reflects how many doses it contained, when it was used and who received it; no administered-dose counts are published for this lot, so counts are not rates and cannot rank lots against each other. Lot numbers in VAERS reports are typed by reporters and are sometimes wrong.
24
Reports
0%
Marked serious
0
With a death outcome
11
Months with reports

Symptom categories in these reports

A report can mention several categories, so the counts add up to more than the number of reports.

CategoryCount%
General / Systemic (non-local)1122%
Musculoskeletal816%
Neurological714%
Injection-site / Local reaction714%
Dermatological (non-injection-site)510%
Cardiac / Cardiovascular48%
Gastrointestinal36%
Allergic / Anaphylactic24%
Psychiatric / Neuropsychiatric24%

Where reports came from

U.S. state of the reporter, where given (top 12).

Wisconsin4
Florida4
Oregon2
Nevada2
Texas2
Kansas1
Colorado1
Washington1
Massachusetts1
Alabama1
Arizona1
New Jersey1

Reports by month received

2022-101
2022-111
2022-126
2023-021
2023-031
2023-053
2023-061
2023-072
2023-083
2023-092
2023-103

Products recorded with this lot

Manufacturer and product as reported in VAERS. Reports listing the lot under more than one product are counted once.

Related

Source: VAERS public data (CDC/FDA), grouped by manufacturer and lot by the Open Source Medicine Foundation; extract 2026-07-04 16:35 UTC. Not medical advice. Report errors via contact.